Literature DB >> 25266999

High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer.

N Alexakis1, I P Gomatos2, S Sbarounis2, K Toutouzas2, S Katsaragakis2, G Zografos2, M M Konstandoulakis2.   

Abstract

BACKGROUND: The objective of this study was to validate current recommendations for the selective use of staging laparoscopy in patients with radiological resectable pancreas head and peri-ampullary tumors.
METHODS: Data from a prospectively collected database (2007-2013) of 136 patients with peri-pancreatic head cancer were analyzed.
RESULTS: Over a 6 year time period, 136 patients were evaluated, 126 patients were deemed radiological resectable and underwent laparotomy and 10 patients were characterized radiological unresectable. There were 111 patients with pancreas head resection and 15 without resection (8 due to extensive vascular involvement and 3 due to peritoneal/liver metastases). The sensitivity, specificity, PPV and NPV of pre-operative radiological imaging in determining unresectability due to liver/peritoneal metastases were 42%, 100%, 100% and 94.7% respectively. There was a significant difference in CA 19-9 values between metastatic and non-metastatic disease (p = 0.020). ROC curve analysis calculated the optimal CA 19-9 cutoff point for predicting metastasis at 215.37 U/ml with a sensitivity of 72.7%, a specificity of 58.3%, PPV of 15.1% and NPV of 95.5%. Tumor diameter was not a significant factor in predicting resectability. Laparoscopy would have been useful in only 5.3% of patients in the present series.
CONCLUSION: High CA 19-9 values (>215 U/ml) and not tumor size should select patients with radiological resectable peri-pancreatic cancer for staging laparoscopy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CA 19-9; Pancreas cancer; Peri-ampullary cancer staging laparoscopy

Mesh:

Substances:

Year:  2014        PMID: 25266999     DOI: 10.1016/j.ejso.2014.09.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  13 in total

1.  The Additional Value of Laparoscopic Ultrasound to Staging Laparoscopy in Patients with Suspected Pancreatic Head Cancer.

Authors:  Gijs A Looijen; Bobby K Pranger; Koert P de Jong; Jan Pieter Pennings; Vincent E de Meijer; Joris I Erdmann
Journal:  J Gastrointest Surg       Date:  2018-03-12       Impact factor: 3.452

2.  The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas.

Authors:  Jayabal Pandiaraja; Subramanian Viswanathan; Thomas Babu Antomy; Sathyamoorthy Thirumuruganand; Dhandapani Subramanian Kumaresan
Journal:  J Clin Diagn Res       Date:  2016-03-01

3.  Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection?

Authors:  Atsushi Oba; Yosuke Inoue; Yoshihiro Ono; Shoichi Irie; Takafumi Sato; Yoshihiro Mise; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2019-11-28       Impact factor: 3.445

Review 4.  Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Victoria B Allen; Kurinchi Selvan Gurusamy; Yemisi Takwoingi; Amun Kalia; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2016-07-06

5.  Predicting positive peritoneal cytology in pancreatic cancer.

Authors:  Eileen A O'Halloran; Tamsin Board; Max Lefton; Karthik Devarajan; Efrat Dotan; Joshua Meyer; Sanjay S Reddy
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-03       Impact factor: 4.322

Review 6.  Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Robert J S Coelen; Anthony T Ruys; Marc G H Besselink; Olivier R C Busch; Thomas M van Gulik
Journal:  Surg Endosc       Date:  2016-02-19       Impact factor: 4.584

Review 7.  Biomarkers in pancreatic adenocarcinoma: current perspectives.

Authors:  Douglas S Swords; Matthew A Firpo; Courtney L Scaife; Sean J Mulvihill
Journal:  Onco Targets Ther       Date:  2016-12-09       Impact factor: 4.147

8.  Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Qing-Long Deng; Shu Dong; Lei Wang; Chen-Yue Zhang; Hai-Feng Ying; Zhao-Shen Li; Xiao-Heng Shen; Yuan-Bao Guo; Zhi-Qiang Meng; Jin-Ming Yu; Qi-Wen Chen
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

9.  Expression and significance of CD44 and p-AKT in pancreatic head cancer.

Authors:  Li Xiaoping; Zhang Xiaowei; Zheng Leizhen; Guo Weijian
Journal:  World J Surg Oncol       Date:  2015-12-15       Impact factor: 2.754

10.  Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?

Authors:  Stefano Crippa; Alessandra Piccioli; Giovanni Guarneri; Enrico Longo; Massimo Falconi
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.